Chemotherapy drug shows promise in relapsing MS

28 April 2017

German pharma major Merck KGaA (MRK: DE) has presented a compelling new efficacy and safety analysis from a study of cladribine in relapsing multiple sclerosis (MS), despite this drug being better known as a chemotherapy treatment.

Up until now, cladribine has been used mainly to treat hairy cell leukemia and occasionally other types of leukemia and lymphoma, marketed under the names Leustat or Litak.

But the new cladribine findings, presented at the Annual Meeting of the American Academy of Neurology, are from a retrospective sub-group analysis of the Phase III CLARITY trial in 289 relapsing MS patients with high disease activity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK